Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Acute Promyelocytic Leukemia: Long-Term Outcomes from the HARMONY Project

Blood blood.2024026186.

https://doi.org/10.1182/blood.2024026186

Published: 2024

Includes: Supplemental data

Journal Articles

Deciphering the Heterogeneity of Acute Myeloid Leukemia through Chromatin Accessibility Profiling

Blood (2024) 144 (Supplement 1): 639.

https://doi.org/10.1182/blood-2024-200415

Published: 2024

Journal Articles

The Prognostic Impact of Myelodysplasia-Related Gene Mutations in Acute Myeloid Leukemia with FLT3 -ITD Mutations

Blood (2024) 144 (Supplement 1): 844.

https://doi.org/10.1182/blood-2024-202362

Published: 2024

Journal Articles

Resistance to FLT3 Inhibitors in FLT3-Mutated AML Is Associated with CD45RA + CD200 - leukemic Cells and Can be Overcome By Combination with SMAC Mimetics

Blood (2024) 144 (Supplement 1): 1565.

https://doi.org/10.1182/blood-2024-200093

Published: 2024

Journal Articles

Active Immunotherapy with Vididencel As Maintenance Treatment in MRD+ AML Patients in CR1 Results in Strong Anti-Tumor Immune Responses and Durable Long-Term Survival in Patients with an Immune Competent Immune Profile

Arjan A. van de Loosdrecht, Eva-Maria Wagner Drouet, Uwe Platzbecker, Tobias A.W. Holderried, Catharina Van Elssen, Aristoteles Giagounidis, Soren Lehmann, Jacqueline Cloos, Hester Van Zeeburg, Jeroen Rovers, Bjorn T. Gjertsen

Blood (2024) 144 (Supplement 1): 2875.

https://doi.org/10.1182/blood-2024-201374

Published: 2024

Journal Articles

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Blood (2023) 142 (Supplement 1): 62.

https://doi.org/10.1182/blood-2023-183029

Published: 2023

Journal Articles

Epigenetic Classification of Acute Myeloid Leukemia Revealed By Genome-Wide Chromatin Profiling

Blood (2023) 142 (Supplement 1): 836.

https://doi.org/10.1182/blood-2023-180336

Published: 2023

Journal Articles

Long-Term Outcome of 1296 Patients with Newly Diagnosed with APL: A Harmony Alliance Study

Luca Guarnera, Soren Lehmann, Konstanze Döhner, Hartmut Döhner, Uwe Platzbecker, Nigel H. Russell, Richard Dillon, Ian Thomas, Gert Ossenkoppele, Marco Vignetti, Edoardo la Sala, Alfonso Piciocchi, Angela Villaverde Ramiro, Laura Tur, Carmelo Gurnari, Lars Bullinger, Jesús María Hernández-Rivas, Maria Teresa Voso

Blood (2023) 142 (Supplement 1): 727.

https://doi.org/10.1182/blood-2023-185121

Published: 2023

Journal Articles

Induction of Cellular and Humoral Immune Responses Is Associated with Durable Remissions in MRD+ AML-Patients after Maintenance Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Arjan A. van de Loosdrecht, Eva Wagner Drouet, Uwe Platzbecker, Tobias A.W. Holderried, Catharina Van Elssen, Aristoteles Giagounidis, Soren Lehmann, Hester Van Zeeburg, Jeroen Rovers, Bjorn T. Gjertsen

Blood (2023) 142 (Supplement 1): 769.

https://doi.org/10.1182/blood-2023-185532

Published: 2023

Journal Articles

Vaccination Using an Allogeneic Leukemia-Derived Dendritic Cell Vaccine, Maintains and Improves Frequencies of Circulating Antigen Presenting Dendritic Cells Correlating with Relapse Free and Overall Survival in AML Patients

Hester Van Zeeburg, Eva Wagner Drouet, Uwe Platzbecker, Tobias A.W. Holderried, Catharina Van Elssen, Aristoteles Giagounidis, Soren Lehmann, Jeroen Rovers, Bjorn T. Gjertsen, Arjan A. van de Loosdrecht

Blood (2023) 142 (Supplement 1): 2957.

https://doi.org/10.1182/blood-2023-188573

Published: 2023

Journal Articles

Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option

Blood (2023) 142 (1): 73–89.

https://doi.org/10.1182/blood.2022016896

Published: 2023

Includes: Supplemental data

Journal Articles

Description of a novel subtype of acute myeloid leukemia defined by recurrent CBFB insertions

Blood (2023) 141 (7): 800–805.

https://doi.org/10.1182/blood.2022017874

Published: 2023

Includes: Supplemental data

Journal Articles

Data-Driven Molecular Hallmarks of Acute Myeloid Leukemia: Biological, Prognostic and Therapeutic Implications

Tom Erkers, Francesco Marabita, Nona Struyf, Mattias Vesterlund, Tojo James, Cornelia Arnroth, Anna Bohlin, Sofia Bengtzén, Albin Österroos, Matthias Stahl, Rozbeh Jafari, Lukas Orre, Yudi Pawitan, Brinton Seashore-Ludlow, Janne Lehtiö, Sören Lehmann, Päivi Östling, Olli Kallioniemi

Blood (2022) 140 (Supplement 1): 6299.

https://doi.org/10.1182/blood-2022-163046

Published: 2022

Journal Articles

Comparison of Data from Fresh and Frozen AML Samples for Functional Drug Testing

Nona Struyf, Cornelia Arnroth, Stephanie Sunandar, Anna Bohlin, Sofia Bengtzén, Sören Lehmann, Olli Kallioniemi, Päivi Östling, Brinton Seashore-Ludlow, Tom Erkers

Blood (2022) 140 (Supplement 1): 6290.

https://doi.org/10.1182/blood-2022-157262

Published: 2022

Journal Articles

Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration

Blood (2022) 140 (Supplement 1): 6053–6055.

https://doi.org/10.1182/blood-2022-165088

Published: 2022

Journal Articles

Use of an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML-Patients Results in MRD Conversion, Improved Relapse-Free Survival and Vaccine Induced Immune Responses to Tumor Antigens

Arjan A. Van de Loosdrecht, Jacqueline Cloos, Eva-Maria Wagner-Drouet, Uwe Platzbecker, Tobias A.W. Holderried, Catharina van Elssen, Aristoteles Giagounidis, Sören Lehmann, Hester J.T. van Zeeburg, Jeroen Rovers, Bjorn T. Gjertsen

Blood (2022) 140 (Supplement 1): 1714–1715.

https://doi.org/10.1182/blood-2022-162169

Published: 2022

Journal Articles

Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in AML Patients Shows MRD Conversion and Improved Survival

Arjan A. Van de Loosdrecht, Jacqueline Cloos, Eva Maria Wagner, Uwe Platzbecker, Tobias A. W. Holderried, Janine van Elssen, Aristoteles Giagounidis, Soren Lehmann, Hester van Zeeburg, Jeroen Rovers, Bjorn T. Gjertsen

Blood (2021) 138 (Supplement 1): 1274.

https://doi.org/10.1182/blood-2021-148333

Published: 2021

Journal Articles

AML displays increased CTCF occupancy associated with aberrant gene expression and transcription factor binding

Huthayfa Mujahed, Sophia Miliara, Anne Neddermeyer, Sofia Bengtzén, Christer Nilsson, Stefan Deneberg, Lina Cordeddu, Karl Ekwall, Andreas Lennartsson, Sören Lehmann

Blood (2020) 136 (3): 339–352.

https://doi.org/10.1182/blood.2019002326

Published: 2020

Includes: Supplemental data

Journal Articles

Identification of Recurrent Alternative RNA Splicing in Adverse-Risk Acute Myeloid Leukemia

Govardhan Anande, Ashwin Unnikrishnan, PhD, Nandan Deshpande, PhD, Sylvain Mareschal, Aarif M. N. Batcha, Tobias Herold, MD, Sören Lehmann, MD PhD, Marc Wilkins, PhD, Jason Wong, PhD, John Pimanda, MBBS, PhD

Blood (2019) 134 (Supplement_1): 457.

https://doi.org/10.1182/blood-2019-129537

Published: 2019

Journal Articles

High-Throughput Functional Ex-Vivo Drug Testing and Multi-Omics Profiling in Patients with Acute Myeloid Leukemia

Tom Erkers, PhD, Brinton Seashore-Ludlow, Nona Struyf, Francesco Marabita, Tojo James, Disha Malani, Mattias Vesterlund, Matthias Stalhl, Yudi Pawitan, Sören Lehmann, MD PhD, Päivi Östling, Janne Lehtiö, Olli Kallioniemi

Blood (2019) 134 (Supplement_1): 4641.

https://doi.org/10.1182/blood-2019-124332

Published: 2019

NARROW

Acute Promyelocytic Leukemia: Long-Term Outcomes from the HARMONY Project

Deciphering the Heterogeneity of Acute Myeloid Leukemia through Chromatin Accessibility Profiling

The Prognostic Impact of Myelodysplasia-Related Gene Mutations in Acute Myeloid Leukemia with FLT3 -ITD Mutations

Resistance to FLT3 Inhibitors in FLT3-Mutated AML Is Associated with CD45RA + CD200 - leukemic Cells and Can be Overcome By Combination with SMAC Mimetics

Active Immunotherapy with Vididencel As Maintenance Treatment in MRD+ AML Patients in CR1 Results in Strong Anti-Tumor Immune Responses and Durable Long-Term Survival in Patients with an Immune Competent Immune Profile

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Epigenetic Classification of Acute Myeloid Leukemia Revealed By Genome-Wide Chromatin Profiling

Long-Term Outcome of 1296 Patients with Newly Diagnosed with APL: A Harmony Alliance Study

Induction of Cellular and Humoral Immune Responses Is Associated with Durable Remissions in MRD+ AML-Patients after Maintenance Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Vaccination Using an Allogeneic Leukemia-Derived Dendritic Cell Vaccine, Maintains and Improves Frequencies of Circulating Antigen Presenting Dendritic Cells Correlating with Relapse Free and Overall Survival in AML Patients

Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option

Description of a novel subtype of acute myeloid leukemia defined by recurrent CBFB insertions

Data-Driven Molecular Hallmarks of Acute Myeloid Leukemia: Biological, Prognostic and Therapeutic Implications

Comparison of Data from Fresh and Frozen AML Samples for Functional Drug Testing

Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration

Use of an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML-Patients Results in MRD Conversion, Improved Relapse-Free Survival and Vaccine Induced Immune Responses to Tumor Antigens

Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in AML Patients Shows MRD Conversion and Improved Survival

AML displays increased CTCF occupancy associated with aberrant gene expression and transcription factor binding

Identification of Recurrent Alternative RNA Splicing in Adverse-Risk Acute Myeloid Leukemia

High-Throughput Functional Ex-Vivo Drug Testing and Multi-Omics Profiling in Patients with Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only